m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05638
 [1]
m6A modification MALAT1 MALAT1 IGF2BP3 : m6A sites Direct Enhancement Non-coding RNA MALAT1 S100A8  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
m6A Target Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) LncRNA View Details
Regulated Target Protein S100-A8 (S100A8) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary circRNA hsa_circ_0004287 was upregulated in peripheral blood mononuclear cells of both AD and psoriasis patients. hsa_circ_0004287 reduced the stability of its host gene Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) by competitively binding to IGF2BP3 with MALAT1 in an N6-methyladenosine (m6A)-dependent manner. Lower levels of MALAT1 promoted the ubiquitination degradation of Protein S100-A8 (S100A8)/S100A9, thereby impeding p38/mitogen-activated protein kinase phosphorylation and macrophage-mediated inflammation.
Responsed Disease Atopic eczema ICD-11: EA80
 Disease Info 
Cell Process Ubiquitination degradation
Inflammation.
In-vitro Model
 RAW 264.7 Mouse leukemia Mus musculus CVCL_0493
In-vivo Model IMQ-induced psoriatic model was constructed by applying 10 mg per ear 5% IMQ for 8 consecutive days, and 6 ug macrophage-specific control or hsa_circ_0004287 plasmid was topically applied every 2 days (5 mice per group per experiment).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
EA80: Atopic eczema 103 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Pimecrolimus Approved [2]
Synonyms
Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin
    Click to Show/Hide
External Link
CID: 6509979
TTD: D0Z4UN
DrugBank: DB00337
 Compound Name Roflumilast Approved [3]
Synonyms
162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast
    Click to Show/Hide
External Link
CID: 449193
TTD: D0R4UW
DrugBank: DB01656
 Compound Name Secukinumab Phase 2 [4]
External Link
TTD: D0Q0OD
 Compound Name cortisone Approved [5]
Synonyms
11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone
    Click to Show/Hide
External Link
CID: 222786
TTD: D0IX6I
DrugBank: DB14681
 Compound Name Prednisone Approved [6]
Synonyms
Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
    Click to Show/Hide
External Link
CID: 5865
TTD: D0IL7L
DrugBank: DB00635
 Compound Name Tralokinumab Approved [6]
Synonyms
CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca
    Click to Show/Hide
External Link
TTD: D0I1ZY
 Compound Name Cromolyn sodium Approved [7]
Synonyms
Altoderm; Cromolyn sodium (topical, atopic dermatitis); Cromolyn sodium (topical, atopic dermatitis), Manhattan Pharmaceuticals
    Click to Show/Hide
External Link
CID: 27503
TTD: D0G7IY
 Compound Name crisaborole Approved [8]
Synonyms
Crisaborole ointment 2%; PF-06930164
    Click to Show/Hide
External Link
CID: 44591583
TTD: D08NWF
DrugBank: DB05219
 Compound Name Upadacitinib Approved [6]
Synonyms
ABT-494
    Click to Show/Hide
External Link
CID: 58557659
TTD: D07JAG
DrugBank: DB15091
 Compound Name Dupilumab Approved [9]
Synonyms
REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis
    Click to Show/Hide
External Link
TTD: D07FUP
 Compound Name Abrocitinib Approved [6]
External Link
CID: 78323835
TTD: D05PCM
DrugBank: DB14973
 Compound Name Ruxolitinib Approved [6]
Synonyms
Ruxolitinib (JAK inhibitor)
    Click to Show/Hide
External Link
CID: 25126798
TTD: D04LKS
DrugBank: DB08877
 Compound Name Tapinarof Approved [10]
Synonyms
GSK-2894512
    Click to Show/Hide
External Link
CID: 6439522
TTD: D03DMB
DrugBank: DB06083
 Compound Name Desonide Approved [11]
Synonyms
Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide
    Click to Show/Hide
External Link
CID: 5311066
TTD: D02JNM
DrugBank: DB01260
 Compound Name Anapsos Approved [12]
Synonyms
Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC
    Click to Show/Hide
External Link
TTD: D00OGX
 Compound Name ARQ-151 Phase 3 [13]
External Link
TTD: DST04F
 Compound Name CBP-201 Phase 3 [14]
External Link
TTD: DF7Y9S
 Compound Name IDP-124 Phase 3 [6]
External Link
TTD: D0XU3D
 Compound Name Lebrikizumab Phase 3 [6]
Synonyms
RG3637
    Click to Show/Hide
External Link
TTD: D0SM8S
 Compound Name SAR231893 Phase 3 [15]
External Link
TTD: D0O9UN
 Compound Name LY-686017 Phase 3 [6]
Synonyms
NK1 antagonist (anxiety/alcoholism), Eli Lilly
    Click to Show/Hide
External Link
CID: 9916461
TTD: D0N8UY
DrugBank: DB12580
 Compound Name Omiganan Phase 2 [6]
Synonyms
CLS-001; MBI-594AN; MX-594AN; Omiganan (topical, acne/rosacea); Omiganan (topical, acne/rosacea), Biowest Therapeutics/Cutanea; Omiganan (topical, acne/rosacea), MIGENIX/Cutanea
    Click to Show/Hide
External Link
CID: 16131445
TTD: D0JW7D
DrugBank: DB06610
 Compound Name Nemolizumab Phase 3 [16]
External Link
TTD: D0B2IR
 Compound Name MABp1 Phase 2 [6]
External Link
TTD: D09AYM
 Compound Name Dupixent Phase 3 [6]
External Link
TTD: D05GZB
 Compound Name Rocatinlimab Phase 3 [17]
Synonyms
AMG 451 / KHK4083
    Click to Show/Hide
External Link
TTD: D03AKW
 Compound Name Bimosiamose Phase 2a [18]
Synonyms
TBC 1269; TBC-1269
    Click to Show/Hide
External Link
CID: 9811353
TTD: D02AUB
DrugBank: DB06197
 Compound Name SAR 444727 Phase 2 [19]
Synonyms
(2E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; (alphaE,3R)-3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1hpyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (alphaE,3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-1-piperidinepropanenitrile; (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile; 1581714-49-9; 1-Piperidinepropanenitrile, 3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; 1-Piperidinepropanenitrile, 3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-alpha-(2,2-dimethylpropylidene)-beta-oxo-, (alphaE,3R)-; AKOS040756908; atuzabrutinib; Atuzabrutinib [INN]; ATUZABRUTINIB [USAN]; BDBM197260; BDBM50589191; CHEMBL4114766; compound 11 [PMID: 35302767]; CS-0204055; GTPL11666; HY-132808; PRN473; PRN-473; SAR444727; SAR-444727; SCHEMBL15515897; SCHEMBL15516108; UNII-YZ68ZB8LWA; US9090621, 125A; YZ68ZB8LWA
    Click to Show/Hide
External Link
CID: 73438222
TTD: DS6V8H
 Compound Name UCB1381 Phase 2 [20]
External Link
TTD: DN9K2Y
 Compound Name Amlitelimab Phase 2 [21]
External Link
TTD: DN2OL8
 Compound Name Q301 Phase 2 [22]
Synonyms
Boc-N-Me-Val-OH; 45170-31-8; Boc-N-methyl-L-valine; N-Boc-N-methyl-L-valine; Boc-MeVal-OH; (S)-2-((tert-Butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid; Boc-N-a-methyl-L-valine; L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; MFCD00038760; n-(tert-butoxycarbonyl)-n-methyl-l-valine; N-Boc-N-methylvaline; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid; PubChem12254; Boc-N-Me-L-Val-OH; Boc-Nalpha-methyl-L-valine; Boc-N-; A-Methyl-L-valine; N-Boc-N-Methyl-L-Val-OH; SCHEMBL59435; DTXSID10426676; ZINC2391126; ANW-41482; AKOS015836686; AKOS015905243; AC-8571; AM82390; AT-5684; CS-W008976; AS-15695; BP-21374; AB0017502; Boc-N-Me-Val-OH, >=99.0% (TLC); DB-038153; 170B318; J-300310; N-alpha-t-Butyloxycarbonyl-N-alpha-methyl-L-valine; Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; (2S)-(tert-Butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (s)-2-(t-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (s)-2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (S)-2-(tert-butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]-3-methyl butanoic acid; (2S)-2-[[(tert-Butoxy)carbonyl](methyl)amino]-3-methylbutanoic acid; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoicacid
    Click to Show/Hide
External Link
CID: 7010608
TTD: DES36M
 Compound Name DMT210 Phase 2 [6]
External Link
TTD: DB5YU0
 Compound Name PF-07038124 Phase 2 [23]
Synonyms
(R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 2415085-44-6; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine; BDBM589740; CS-0433935; Example 4 [US2020108083A1]; GLXC-25702; GTPL11950; HY-144683; M6ZU548FWD; PF 07038124 [WHO-DD]; PF07038124; PF-07038124; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; UNII-M6ZU548FWD; US11559538, Example 4
    Click to Show/Hide
External Link
CID: 148293990
TTD: D81WBS
 Compound Name ATI-502 Phase 2 [24]
Synonyms
ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one
    Click to Show/Hide
External Link
CID: 46851625
TTD: D6N5UC
 Compound Name Zabedosertib Phase 2 [25]
Synonyms
1931994-81-8; 2-Pyridinecarboxamide, N-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-; AKOS040755617; BAY 1834845; BAY1834845; BAY-1834845; BDBM395297; CS-0198831; D96922; EX-A5143; GTPL11415; HY-139374; MFCD32900903; MS-28697; N-(6-(1-Hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methanesulfonyl)ethyl)- 2H-indazol-5-yl)-6-(trifluoromethyl)pyridine-2- carboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)picolinamide; N-[6-(1-hydroxy-1-methyl-ethyl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-Hydroxy-2-propyl)-2-[2-(methylsulfonyl)ethyl]-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide; N1GRK350ZM; OQAMEEFUUFJZRS-UHFFFAOYSA-N; SB74225; SCHEMBL17785221; SY323200; UNII-N1GRK350ZM; US10308634, Example 12; Zabedosertib; Zabedosertib [INN]
    Click to Show/Hide
External Link
CID: 121364961
TTD: D5XVM6
 Compound Name E6005 Phase 2 [26]
Synonyms
Lotamilast; 947620-48-6; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7
    Click to Show/Hide
External Link
CID: 24864553
TTD: D0TT4H
DrugBank: DB12776
 Compound Name K-201 Phase 2 [27]
Synonyms
DKKLXCRMAXNIJF-UHFFFAOYSA-N; UNII-0I621Y6R4Q; K201; 0I621Y6R4Q; 1038410-88-6; K 201; SCHEMBL194018; CHEMBL2440857; DTXSID90146108; K-201, Moberg; Dermatological drug combination (kaprolac, atopic dermatitis), Moberg; Urea + PEG/propylene glycol formulation (atopic dermatitis), Moberg; JTV 519
    Click to Show/Hide
External Link
CID: 9868902
TTD: D0MT1Q
 Compound Name JNJ-26113100 Phase 2 [28]
Synonyms
Dermatitis agent (oral), Alza
    Click to Show/Hide
External Link
TTD: D0K9KN
 Compound Name SRD-441 Phase 2 [29]
Synonyms
Aureostat; ST-441; STP-01a; Protease inhibitor (atopic dermatitis), Surface Therapeutics
    Click to Show/Hide
External Link
TTD: D0J6ZA
 Compound Name S-777469 Phase 2 [30]
External Link
CID: 57331749
TTD: D0J6KZ
 Compound Name PMX-53 Phase 2 [31]
Synonyms
YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam
    Click to Show/Hide
External Link
CID: 6918468
TTD: D0G2XE
 Compound Name NCX 1022 Phase 2 [32]
External Link
TTD: D0E8YH
 Compound Name ALX-101 Phase 2 [6]
Synonyms
Rovazolac; UNII-W51K389XIL; W51K389XIL; Rovazolac [INN]; GTPL9625; SCHEMBL15242823; ZUMNJDGBYXHASJ-UHFFFAOYSA-N; example 36 [WO2013130892]; HY-109073; CS-0033536; A-110; ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate; ethyl 2-(5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; ethyl 2-(5-(3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; Ethyl 2-(5-(3'-(methylsulfonyl)-(1,1'-biphenyl)-4-yl)-3-(trifluoromethy
    Click to Show/Hide
External Link
CID: 89792952
TTD: D0CT5O
 Compound Name ATI-502 Phase 2 [6]
External Link
TTD: D0CG0K
 Compound Name Cerdulatinib Phase 2 [6]
Synonyms
PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals
    Click to Show/Hide
External Link
CID: 44595079
TTD: D0BI3N
DrugBank: DB15499
 Compound Name ASB17061 Phase 2 [33]
External Link
TTD: D0B1OH
 Compound Name RVT-505 Phase 2 [6]
External Link
TTD: D0AF5P
 Compound Name Q-301 Phase 2 [6]
External Link
TTD: D09QMX
 Compound Name PAC-14028 Phase 2 [34]
External Link
CID: 56649347
TTD: D09BDE
DrugBank: DB12428
 Compound Name MM36 Phase 2 [6]
Synonyms
CHEMBL225555
    Click to Show/Hide
External Link
CID: 57855696
TTD: D09ALR
DrugBank: DB14987
 Compound Name BRT-FC-83C Phase 2 [35]
Synonyms
Dermatological agent (topical, atopic dermatitis), Biomed Research & Technologies
    Click to Show/Hide
External Link
TTD: D08YJN
 Compound Name ADX-914 Phase 2 [36]
External Link
TTD: D08GVP
 Compound Name HL-009 Phase 2 [37]
Synonyms
Adenosylcobamide; Adenosylcobalamin (vitamin B12) (nanoliposome, allergy), HanAll
    Click to Show/Hide
External Link
TTD: D07PFG
 Compound Name GW-870086-X Phase 2 [38]
Synonyms
GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline
    Click to Show/Hide
External Link
TTD: D06XSB
 Compound Name DPK-060 Phase 2 [39]
Synonyms
DP-9011; DP-9012; DP-9013; DP-9011-DP-9013 series (atopic dermatitis/impetigo), DermaGen
    Click to Show/Hide
External Link
TTD: D06XMW
 Compound Name Santalum Phase 2 [6]
External Link
TTD: D06OVF
 Compound Name TS-022 Phase 2 [40]
Synonyms
Prostaglandin derivative (topical, dermatitis), Taisho
    Click to Show/Hide
External Link
CID: 16049813
TTD: D06GNF
 Compound Name BMX-010 Phase 2 [6]
Synonyms
UNII-BN93L2NT5I; BN93L2NT5I; Manganese(III)meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin chloride; Manganese(4+), chloro((2,2',2'',2'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis(1-ethylpyridiniumato))(2-))-, tetrachloride, (sp-5-12)-; 219818-60-7
    Click to Show/Hide
External Link
CID: 10033875
TTD: D06FER
 Compound Name ANB-020 Phase 2 [6]
Synonyms
etokimab
    Click to Show/Hide
External Link
TTD: D05TSG
 Compound Name PRO22 Phase 2 [6]
External Link
TTD: D05MJS
 Compound Name LEO-29102 Phase 2 [41]
External Link
CID: 66829720
TTD: D04XVJ
 Compound Name LAS-41004 Phase 2 [42]
Synonyms
Anti-inflammatory (psoriasis/atopic dermatitis), Almirall
    Click to Show/Hide
External Link
TTD: D04TJL
 Compound Name Cis-urocanic acid Phase 2 [43]
Synonyms
ProtoCure; ProtoCure (emulsion, atopic dermatitis), Biocis Pharma; Anti-inflammatory (topical emulsion, dermatological disease), BioCis; ProtoCure (emulsion, atopic dermatitis/psoriasis), Biocis Pharma; ProtoCure (emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma; Cis-UCA (topical emulsion, atopic dermatitis/psoriasis), Laurantis; Cis-urocanic acid (topical emulsion, atopic dermatitis/psoriasis), BioCis Pharma
    Click to Show/Hide
External Link
CID: 1549103
TTD: D04CQV
 Compound Name AN0128 Phase 2 [44]
Synonyms
Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane
    Click to Show/Hide
External Link
CID: 11704019
TTD: D03VPJ
 Compound Name GBR 830 Phase 2 [6]
External Link
TTD: D03DUI
 Compound Name TA-7906 Phase 2 [45]
Synonyms
T-2585; PDE4 inhibitor (skin disease), Maruho; PDE4 inhibitors (inflammation), Tanabe Seiyaku; T-2585.HCl
    Click to Show/Hide
External Link
TTD: D02POH
 Compound Name PF-3893787 Phase 2 [6]
Synonyms
PF-03893787; PF-3826719
    Click to Show/Hide
External Link
CID: 24745335
TTD: D02DTQ
DrugBank: DB15027
 Compound Name VTB-38543 Phase 2 [6]
External Link
TTD: D01XMC
 Compound Name AN-2898 Phase 2 [46]
Synonyms
PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor
    Click to Show/Hide
External Link
CID: 24806574
TTD: D00JED
 Compound Name KP-413 Phase 1/2 [47]
External Link
TTD: D0I3HI
 Compound Name REGN-846 Phase 1/2 [48]
Synonyms
RENG-846; SAR-302352; SAR-302532
    Click to Show/Hide
External Link
TTD: D06DBJ
 Compound Name ZPL521 Phase 1/2 [6]
External Link
TTD: D02XBN
 Compound Name PF-07295324 Phase 1 [49]
External Link
TTD: DXVA93
 Compound Name PF-07242813 Phase 1 [50]
External Link
TTD: DUJ16L
 Compound Name PF-07275315 Phase 1 [51]
External Link
TTD: DIWU14
 Compound Name STMC-103H Phase 1 [52]
External Link
TTD: D89XBL
 Compound Name UCB9741 Phase 1 [53]
External Link
TTD: D62JOV
 Compound Name PF-07264660 Phase 1 [54]
External Link
TTD: D1LP4B
 Compound Name PF-06817024 Phase 1 [6]
External Link
TTD: D0W6YR
 Compound Name EDP1066 Phase 1 [6]
External Link
TTD: D0UD1J
 Compound Name SNA-125 Phase 1 [6]
External Link
TTD: D0Q0IM
 Compound Name SAR444656 Phase 1 [55]
External Link
TTD: D0CW9M
 Compound Name KPL-716 Phase 1 [6]
External Link
TTD: D09KEW
 Compound Name SB414 Phase 1 [6]
External Link
TTD: D02UYM
 Compound Name Quinazoline derivative 13 Patented [56]
Synonyms
PMID26936077-Compound-24
    Click to Show/Hide
External Link
CID: 60161489
TTD: D0P2BJ
 Compound Name Piperazine derivative 5 Patented [56]
Synonyms
PMID26936077-Compound-16
    Click to Show/Hide
External Link
CID: 53244427
TTD: D0LT5Y
 Compound Name P-1 Discontinued in Phase 3 [57]
Synonyms
Zemaphyte; Zemaphyte (P1)
    Click to Show/Hide
External Link
CID: 200882
TTD: D03HVN
 Compound Name AVAC Discontinued in Phase 2 [58]
External Link
TTD: D0L8WA
 Compound Name GW842470X Discontinued in Phase 2 [30]
External Link
TTD: D0F3BY
 Compound Name Dermolastin Discontinued in Phase 2 [59]
External Link
CID: 188403
TTD: D0B9EH
 Compound Name CD-581 Discontinued in Phase 1 [60]
Synonyms
1-(Eicosa-5,8,11-triynoyl)-4-(2-hydroxyethyl)piperazine; 4-(1-Oxo-5,8,11-eicosatriynyl)-1-piprazineethanol
    Click to Show/Hide
External Link
TTD: D0F5NB
 Compound Name RESP-6000 Investigative [61]
External Link
TTD: D0ZE3S
 Compound Name J-555Y Investigative [61]
External Link
TTD: D0U3TE
 Compound Name SWT-01113 Investigative [61]
External Link
TTD: D0S4PZ
 Compound Name PBI-1308 Investigative [61]
Synonyms
PBI-1308 (dermatological, dermatological diseases); PBI-1308 (dermatological, dermatological diseases), Darier/ProMetic
    Click to Show/Hide
External Link
TTD: D0RB2H
 Compound Name DPS-201 Investigative [61]
External Link
TTD: D0GV0H
 Compound Name RTU-1096 Investigative [62]
External Link
TTD: D0F8KR
 Compound Name KF-66490 Investigative [63]
Synonyms
K-34; PDE 4 inhibitors (dermatitis/rheumatoid arthritis); PDE 4 inhibitors (dermatitis/rheumatoid arthritis), Kyowa Hakko Kirin
    Click to Show/Hide
External Link
CID: 281833
TTD: D0E5VP
 Compound Name MLR-1130 Investigative [61]
Synonyms
Non-steroidal antiinflammatory (topical, atopic dermatitis), Melior
    Click to Show/Hide
External Link
TTD: D0DA3D
 Compound Name AP-1189 Investigative [64]
Synonyms
AP-1089; Melanocortin receptor-1 modulator (oral, inflammation), Action Pharma
    Click to Show/Hide
External Link
TTD: D09QPE
 Compound Name DM-107 Investigative [65]
Synonyms
MDPK-67; MDPK-67b; Kallikrein 2 inhibitor (anticancer), Med Discovery; Kallikrein 2 inhibitor (dermatological disorders), Dermadis
    Click to Show/Hide
External Link
TTD: D03OMK
 Compound Name SWT-05141 Investigative [61]
External Link
TTD: D03DOW
 Compound Name C-0333158 Investigative [61]
External Link
TTD: D02YRX
References
Ref 1 Hsa_circ_0004287 inhibits macrophage-mediated inflammation in an N(6)-methyladenosine-dependent manner in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2022 Jun;149(6):2021-2033. doi: 10.1016/j.jaci.2021.11.024. Epub 2021 Dec 23.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6783).
Ref 3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6962).
Ref 4 ClinicalTrials.gov (NCT01359943) Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate
Ref 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5171).
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 ClinicalTrials.gov (NCT00745199) Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus. U.S. National Institutes of Health.
Ref 8 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
Ref 9 2017 FDA drug approvals. Nat Rev Drug Discov. 2018 Feb;17(2):81-85. doi: 10.1038/nrd.2018.4. Epub 2018 Jan 19.
Ref 10 ClinicalTrials.gov (NCT02564042) A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis.
Ref 11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7066).
Ref 12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 13 ClinicalTrials.gov (NCT04804605) Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE). U.S. National Institutes of Health.
Ref 14 ClinicalTrials.gov (NCT05614817) A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy. U.S.National Institutes of Health.
Ref 15 ClinicalTrials.gov (NCT02134028) Long-Term Safety Evaluation of Dupilumab in Patients With Asthma. U.S. National Institutes of Health.
Ref 16 ClinicalTrials.gov (NCT03989206) Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis. U.S. National Institutes of Health.
Ref 17 ClinicalTrials.gov (NCT05633355) A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged >= 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit). U.S.National Institutes of Health.
Ref 18 Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
Ref 19 ClinicalTrials.gov (NCT04992546) A Randomized, Intra-patient, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis. U.S.National Institutes of Health.
Ref 20 ClinicalTrials.gov (NCT05277571) A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B). U.S.National Institutes of Health.
Ref 21 OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753.
Ref 22 ClinicalTrials.gov (NCT03571620) Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients. U.S. National Institutes of Health.
Ref 23 ClinicalTrials.gov (NCT05375955) A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS. U.S.National Institutes of Health.
Ref 24 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
Ref 25 ClinicalTrials.gov (NCT05656911) A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Phase 2a Study to Investigate Efficacy and Safety of Zabedosertib (BAY 1834845) for the Treatment of Adult Patients With Moderate-to-severe Atopic Dermatitis. U.S.National Institutes of Health.
Ref 26 ClinicalTrials.gov (NCT01461941) A Phase 2 Study of E6005 in Patients With Atopic Dermatitis. U.S. National Institutes of Health.
Ref 27 ClinicalTrials.gov (NCT01067833) Phase 2 Study of Oral K201 for Prevention of AF Recurrence. U.S. National Institutes of Health.
Ref 28 ClinicalTrials.gov (NCT00455429) An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis. U.S. National Institutes of Health.
Ref 29 ClinicalTrials.gov (NCT00882245) Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis. U.S. National Institutes of Health.
Ref 30 Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
Ref 31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 579).
Ref 32 Clinical pipeline report, company report or official report of NicOx SA.
Ref 33 ClinicalTrials.gov (NCT01756898) A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis. U.S. National Institutes of Health.
Ref 34 ClinicalTrials.gov (NCT02052531) Efficacy and Safety Study of PAC-14028 Cream in Dermal Pruritus. U.S. National Institutes of Health.
Ref 35 ClinicalTrials.gov (NCT00883311) A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis. U.S. National Institutes of Health.
Ref 36 ClinicalTrials.gov (NCT05509023) A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof-of-Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects With Moderate to Severe Atopic Dermatitis. U.S.National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT01568489) Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis. U.S. National Institutes of Health.
Ref 38 ClinicalTrials.gov (NCT01299610) A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo. U.S. National Institutes of Health.
Ref 39 ClinicalTrials.gov (NCT01447017) A Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis. U.S. National Institutes of Health.
Ref 40 ClinicalTrials.gov (NCT00914186) Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC). U.S. National Institutes of Health.
Ref 41 ClinicalTrials.gov (NCT01037881) LEO 29102 Cream in the Treatment of Atopic Dermatitis. U.S. National Institutes of Health.
Ref 42 ClinicalTrials.gov (NCT01119339) Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis. U.S. National Institutes of Health.
Ref 43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024035)
Ref 44 Clinical pipeline report, company report or official report of Anacor Pharmaceuticals.
Ref 45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024588)
Ref 46 ClinicalTrials.gov (NCT01301508) Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis. U.S. National Institutes of Health.
Ref 47 ClinicalTrials.gov (NCT00932074) A Study to Determine the Safety, Tolerability and Efficacy of KP 13 in Subjects With Atopic Dermatitis(AD). U.S. National Institutes of Health.
Ref 48 ClinicalTrials.gov (NCT01605708) Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis. U.S. National Institutes of Health.
Ref 49 ClinicalTrials.gov (NCT05206604) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, VEHICLE-CONTROLLED, FIRST-IN-HUMAN, MULTIPLE-DOSE STUDY, TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS, OF TOPICALLY ADMINISTERED PF-07295324 AND PF-07259955, IN HEALTHY ADULT PARTICIPANTS. U.S.National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT04668066) A PHASE 1 FIRST IN HUMAN, RANDOMIZED, DOUBLE BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF 07242813 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS. U.S.National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT05411588) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07275315 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health.
Ref 52 Clinical pipeline report, company report or official report of Siolta Therapeutics.
Ref 53 ClinicalTrials.gov (NCT04643457) A Phase I/IIA, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeated-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants (Part A) and in Study Participants With Moderate-to-Severe Atopic Dermatitis (Part B). U.S.National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT05496738) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07264660 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health.
Ref 55 Clinical pipeline report, company report or official report of Sanofi
Ref 56 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
Ref 57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006996)
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014452)
Ref 59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018071)
Ref 60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008118)
Ref 61 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 62 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
Ref 63 Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol. 2009 Jan;9(1):55-62.
Ref 64 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 282).
Ref 65 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2372).